Objective: To identify the decision-making needs of women about the use of natural health products (NHP) at menopause and to develop a decision aid responsive to their needs.
INTRODUCTION I
n the last decade, the interest of individuals toward the use of natural health products (NHP) has grown considerably, 1 and middle-aged women who are living through menopause are no exception. 2 Many women exhibiting menopausal symptoms such as hot flashes, mood swings, or insomnia may consider using one or more NHP. 3, 4 Although estrogen therapy remains the most effective treatment for relieving menopausal hot flashes, there is a growing interest in nonhormonal therapies. 5 Consequently, more than 100 new NHP aimed at women in menopause appeared in the American market between 1998 and 2000. 6 Decision making about the use of NHP to manage menopausal symptoms is rife with uncertainty. 7 A recent systematic review concluded that data were insufficient to support the effectiveness of any complementary and alternative therapy for the management of menopausal symptoms. 5 Decision making in the context of scientific uncertainty (i.e., when convincing data are in conflict or nonexistent) is influenced by other factors such as realistic expectations, values associated with potential risks and benefits, undue pressure from others, as well as the desired role in decision-making. 8 Thus, in the face of uncertainty, decision support often requires (1) evidence-based information about options, benefits, risks, and the degree of scientific uncertainty so as to promote informed decision making based on realistic expectations; (2) values clarification to determine which option has outcomes that are more consistent with an individual's preferences; and (3) guidance to facilitate patient participation in decision making.
Consequently, new interventions that address gaps in mutual understanding of facts and values between patients and health professionals have been developed. 9, 10 One such intervention is a "patient decision aid" that aims to prepare patients for discussing health decisions with their practitioner by helping patients understand the facts (e.g., options, benefits, harms) and clarifying their values associated with their options. 10 The goal is to arrive at a decision that is informed by the best evidence and consistent with the patient's values. Patient decision aids increase individuals' knowledge of the options, promote the active participation of individuals in the decision to be made, lead to more realistic expectations, improve the match between the choice that is made and the individual's values, and reduce decisional conflict. The individual's values refer to the importance this individual place on benefits and harms that are associated with the options. However, the Cochrane Inventory of more than 500 patient decision aids and literature review conducted for this study found no decision aids focused on the use of NHP by menopausal women. Consequently, the aims of this study were to identify the decision-making needs of women regarding the use of NHP at menopause, to develop a decision aid to address their needs, and to determine its acceptability.
MATERIALS AND METHODS
In health services research and most specifically in studies that aim at improving our understanding of how individuals make health-related decisions, there is a growing body of literature that emphasizes the lack of theory. 11 In turn, this lack of theory is said to be hampering our interpretation of change as well as the development of effective interventions. 12 Therefore, guided by the Ottawa Decision Support Framework (ODSF), 8 this study used (1) qualitative methods to identify the decision-making needs of women facing decisions about using NHP; (2) a process of decision aid development that followed the recent guidelines established by the International Patient Decision Aid Standards (IPDAS) Collaboration 13 ; and (3) group consultation for assessing the acceptability of the decision aid. The ODSF is a 3-step process that comprises (1) assessing determinants of decision making (e.g., perception of the decision, perception of others, resources needed to make the decision, characteristics of the individual); (2) addressing identified decisional needs; and (3) evaluating the decision quality and progress in decision making.
Data collection involved focus groups, individual interviews, and a group consultation. The semistructured interview guide used in the focus groups and individual interviews consisted of a standardized set of questions for conducting decision-making needs assessments based on the ODSF. 14 Focus groups were conducted in 2 Canadian cities with peri-or postmenopausal women ages 45 to 64 years who were considering the use of NHP for menopausal reasons. Women were recruited using bulletin boards in health organizations, local newspapers, radio stations, and word of mouth. A purposeful sampling strategy sought to recruit 15 key informants representing groups of individuals who may advise and/or guide women on use of NHP (e.g., physicians, nurses, pharmacists, NHP store owners, representatives of women's advocacy groups, and policymakers). Previous studies have documented the potential influence of these individuals on the decision-making process of women regarding complementary and alternative therapies at menopause. 15 In order to locate these key informants, we used a snowball approach, which means that we asked "wellsituated people" in each group to identify potential individuals. 16 We contacted identified individuals until we obtained a minimum of 2 individuals per targeted group. Given the lack of homogeneity among these key informants, the decision was made to conduct individual interviews. These interviews were conducted in French or English, depending on the preference of the interviewee.
According to IPDAS collaboration, quality decision aids are developed based on the decisional needs as perceived by the target audiences, review by individuals who have made the decision, and pilot testing at the time of decision making. 13 Higher-quality decision aids include information on the options and their outcomes (benefits and harms), prob-abilities of outcomes, help with clarifying values associated with outcomes, and explicit guidance in the process of decision making. Additional IPDAS criteria focus on balanced presentation of options, use of scientific evidence, disclosure of potential conflicts of interest, and plain language. Finally, quality decision aids are evaluated to determine their effect on decision quality (informed and values based) and the decision-making process.
Focus groups and individual interviews were taperecorded and transcribed verbatim. Content analysis of each transcript was guided by the ODSF. The unit of analysis was the individual focus group or key informant interview. In this qualitative study, our intention was to maximize the potential for triangulation of views from the women themselves and key informants in the field. 17 Participants were sent the transcript with a summary of the identified themes and were asked to verify their accuracy (response rate: 65% of women, 73% of key informants). Based on the identified themes, a prototype of a first decision aid was produced. Menopausal women were recruited from 2 community groups to participate in group consultation sessions aimed at assessing the acceptability of the first prototype of the patient decision aid. In addition to an open discussion that provided feedback on the decision aid, they were asked to complete a standardized acceptability survey. 18 This survey elicits feedback on the amount, length, clarity, balanced presentation, and usefulness of the information for decision making. The acceptability survey and participant demographics were analyzed descriptively using SAS v9.1 (Cary, NC). Approval was received from the ethics review committees at the Ottawa Hospital in Ottawa and at Hôpital St-François d'Assise in Québec City, Canada.
RESULTS

Characteristics of participants
Of the 49 women who agreed to participate, 40 attended 1 of 6 focus groups offered in French (n ϭ 3) or English (n ϭ 3). The typical woman participant was 56 years old, married, with postsecondary education, and in good health ( Table 1) . On the Menopause-Specific Quality of Life Questionnaire (MENQOL), 19 the mean scores were as follows: vasomotor symptoms 2.54 Ϯ 1.76, psychosocial symptoms 2.67 Ϯ 1.37, physical symptoms 3.30 Ϯ 1.18, and sexual symptoms 3.14 Ϯ 1.83. The MENQOL is a validated instrument that tests physical, vasomotor, psychosexual, and sexual domains of quality of life. For each domain, a minimum score of 0 corresponds to no symptoms and a maximum score of 7 corresponds to extremely bothersome symptoms.
Of 19 key informants invited to participate, 15 were interviewed: 3 representatives from women's advocacy groups, and a francophone and anglophone participant for each of the following groups: nurses, gynecologists, family physicians, pharmacists, NHP store owners, and policymakers. Most key informants were female (n ϭ 13) with a median age of 53 (range 30-68). Two group consultation sessions were conducted with 11 women from community- based groups, ages 45-64, who provided comments on the acceptability of the first prototype of the patient decision aid. Table 2 shows frequency of difficult decisions about the use of NHP at menopause that were identified, and Table 3 , the sources of difficulty in making these decisions. Consistent with the ODSF, participants identified that unrealistic expectations of risks associated with NHP and poor understanding of information influenced women's perception of the decision. Difficulties related to having adequate support and advice from others were due to close-mindedness of physicians in the discussion of NHP, conflicting opinions from others, societal pressures to look young and healthy, and lack of a credible person for advice. Limited resources that negatively influenced the decision making included lack of scientific evidence, questionable quality of information, costs associated with purchasing NHP as well as consultation with NHP practitioners, and inadequate time for deliberating on the decision. Finally, menopausal symptoms such as memory problems or being sleep deprived were described by key informants as interfering with being able to make decisions.
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Types of decisions and sources of difficulty regarding the use of NHP at menopause
The role of others in NHP decision making
In all focus groups, women expressed that they wanted to play an active role in making decisions about the use of NHP at menopause. One woman shared, "It's because if your doctor says to you 'don't touch that' and you wanted to try something, I know what I would do because I'm capable of taking my own health in hand." However, in 3 focus groups, women also reported wanting to share decisionmaking with their physician. For example, one woman said, "I prefer to do it in conjunction with my doctor, but with my doctor being informed and having the information there so I can get the information I want."
When the women were asked who else was involved in making their decisions about the use of NHP, they identified equally their partner, female friends, and physician (n ϭ 3/6 focus groups), then the nurse, their families, and their Lack of time for "So when I do get in to see her with all of those things I checked off, how much time women and health time is she going to have now? I think the time spent consulting the family professionals physicians is going to diminish hugely for our age group and people behind us. They do not have time." (FG #6) "Many women are in the sandwich situation and the last thing that they put ahead of everything else, is themselves. And this is part of self-care, looking at these issues. So time is a problem." (KI #12) Characteristics Menopausal "The symptoms that they're suffering from make it difficult for them to make of women symptoms interfere decisions. Because they're sleep deprived or they think they got memory problems, they're forgetting things." (KI #9) ODSF, Ottawa Decision Support Framework.
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pharmacists (n ϭ 2/6 focus groups), followed by the naturopath and NHP store owners (n ϭ 1/6). Key informants cited the same individuals or groups of individuals as the women and the most frequently identified were family (n ϭ 11/15) followed by physicians (n ϭ 10/15).
Resources for NHP decision making
In the focus groups and interviews, resources currently used by women to make a decision about NHP at menopause were (from most to least frequent): magazines, Internet, pharmacies, women's groups, physicians, family/friends, and naturopaths. When asked what was needed to better support these types of decisions, the resources most frequently identified by women were (1) more support from physicians; (2) better information (objective, reliable, and credible); and (3) individuals they perceived as being adequately qualified in the area (Table 4) . Women also expressed their desire for tighter government regulations regarding the use of NHP at menopause and their lack of confidence resulting from the fact that these products are not regulated. Key informants identified similar resources needed to support NHP decision making as did the women (Table 4) .
Patient decision aid
The results from the needs assessment were used to design a patient decision aid focused on the decision "whether or not to take NHP" for menopausal symptoms. The paperbased prototype decision aid provided (1) information on the available options for menopausal women, including the probabilities of outcomes when available, lack of scientific evidence for many NHP, and possible interaction effects between medications and NHP; (2) a balance scale to clarify values associated with outcomes of options; (3) a structured process to follow when making the decision; and (4) questions to self-assess the severity of menopause-related health issues. 20 Of the 11 women who provided feedback on the acceptability of the first prototype of the patient decision aid, 9 rated the presentation of the information and usefulness of the decision aid as good to excellent. Seven women said that the sections presenting NHP and menopause were complete and useful. During the consultations, participants suggested removing the section aimed at educating women about the concept of probabilities and requested more information about specific products, even if the evidence was not conclusive. The decision aid was modified according to their suggestions and included a list of the most commonly used NHP at menopause with the level of evidence that is available for each one of them (Fig. 1) . [21] [22] [23] 
DISCUSSION
This study is the first focused specifically on the decision-making needs of women regarding the use of NHP at menopause and the difficulties associated with making this decision. Overall, results from this study suggest that women are actively involved in decisions regarding the use of NHP at menopause and that these decisions are perceived as difficult by women and those who provide advice and/or guidance to them. Many of the factors interfering with decision making (e.g., inadequate information, unclear values, and conflicting opinions of others) could be addressed by the development of a patient decision aid that would guide women in the process of decision making. Menopausal women clearly identified that the information to support decision making, including patient decision aids, should be made available through the Internet, women's magazines, and directly from health care professionals.
Although the decision aid addresses some factors causing menopausal women difficulty in making decisions about NHP, it does not address financial issues or directly address inadequate time for decision making. The current prototype
LÉGARÉ ET AL. 746 TABLE 4. RESOURCES NEEDED TO SUPPORT NATURAL HEALTH PRODUCTS (NHPS) DECISION-MAKING
Focus groups
Key informants (n ϭ 6) (n ϭ 15)
More support from physicians 6 (100) 1 ( Step 2. Getting the facts When learning about the benefits and risks of natural health products that have been used by women during menopause. It is important to know that the quality of the information varies. This quality depends on the number and types of research studies that have been done. 
Common name (latin)
Black cohosh (cimicifiga racemosa, Actaea racemosa) It is not possible to identify the benefits or risks associated with the use of these products.
Ginseng (Panax ginseng) Wild yam (Dioscoreaceae villosa) Green tea (Camellia sinensis)
Garlic (Alium sativum)
Evening primrose oil (Oenothera biennis)
Kava (Piper methysticum)
Research studies are needed.
Studies show that evening primrose oil does not decrease hot flashes.
The benefits and the risks related to these products are not known. Research studies are needed.
Possible benefits
Decreases hot flashes due to menopause.
Possible risks
Soya does not have any known long-term toxic effects.
Side-effects may include nausea, constipation, and bloating.
Restrictions or warnings
Consult your physician before use if you:
-have or have had breast or uterine cancer -have an allergy to aspirin or to the ranunculaceae family -suffer from endometriosis -are using a hormone replacement therapy for menopause (hormones) -suffer from epilepsy -are taking medication for hypertension -have heart or liver problems 
Common name (latin)
Health Canada and similar agencies in other countries have reports that kava may cause serious liver dysfunction and as a result have withdrawn it from the market.
Given that NHPs may have adverse events and interactions, please discuss with your healthcare provider if you are considering taking any natural health product.
of the patient decision aid has the potential to enhance support from practitioners, given that it has an interactive worksheet that can be used to facilitate communication between practitioners and patients. Previous evaluation of patient-practitioner dialogue, when patients were prepared using a similar decision-making worksheet for discussing decisions about using hormone replacement therapy, found that compared to controls, the dialogue was more 2-way and the key factors influencing the decision (e.g., patients' knowledge, clarity of their values, and adequate support from others) were more likely to be discussed. 24 Therefore, if women share their NHP worksheet with their practitioner, there is the potential for more discussion about the decision being stimulated. However, strategies are also required to enhance practitioner skills 25, 26 in addressing the decisionmaking needs of menopausal women. Such strategies include counseling and/or referring these women to patient decision aids such as the one developed in this study.
The vast majority of women we met in the focus groups said they wanted to play an active role in making the decision to take NHP during menopause. This is congruent with previous research in this field. 27 However, women also expressed the need to be supported in their decision-making process by their physician or by their immediate circle (female friends, family). Unfortunately, they do not perceive that physicians are open to discussing this subject. This observation has been noted in other studies. 28 Therefore, it would be important to plan interventions with physicians to provide them with the tools and abilities to facilitate open discussion on the subject. 29 It is possible that a greater openmindedness or ability to tackle patients' expectations toward NHP on the part of physicians might decrease the risk of undesirable interactions between NHP and medications. 30, 31 In this study, women expressed their desire for tighter government regulation regarding the use of NHP at menopause and their lack of confidence resulting from the fact that these products are not currently regulated. These findings suggest that women who participated in this study were favorable toward regulation; however, they also suggest that these women had not learned of the new regulations by Health Canada concerning NHP, which came into effect in January 2004. Therefore, information about NHP regulations needs to be communicated to the public, and patient decision aids provide a medium for doing so. For example, in the patient decision aid that was developed, the section on kava highlights the Health Canada stop-sale order for all products containing kava and provides the URL for access to more detailed information.
Limitations and strengths of the study
This is a qualitative study in which the women were recruited using a "snowball" strategy and publicity in various media. As a result, we had a fairly homogeneous group of women who were married, educated, in the middle-income range, and in good-to-excellent health. Unfortunately, we did not assess other potentially important characteristics of women such as race and religion. Therefore, we cannot assume that our results are transferable to other populations. However, this study followed a rigorous process that has proven useful and effective for producing decision aids that were shown to improve the decision-making process of individuals facing difficult decisions. Also, this study was focused on the decisional needs of women regarding NHP. Therefore, it cannot inform us as to the decisional needs of physicians themselves regarding NHP. More specifically, the strengths of our study are (1) guidance based on a conceptual framework focused on decisional conflict; (2) member checking by participants of the results; and (3) feedback on the prototype decision aid developed, based on identified needs of women facing this decision. Consequently, we believe that the decision aid about NHP during menopause, produced in French and in English, has the potential to fill a growing need among women who are considering the use of NHP.
CONCLUSIONS
Menopausal women describe decisions about the use of NHP as difficult and express the need for support with decision making. In particular, they are looking for written information as well as someone well informed on both medical and NHP options with whom they can discuss the decision. Patient decision aids, such as the one developed in this study, are effective for improving knowledge, expectations, and engaging women in a stepped process of decision making. However, given the limited evidence on the effectiveness of NHP at menopause, this decision is likely to continue to be a challenging one. Furthermore, women are mentioning that, in addition to the need for resources such as the decision aid, they prefer to have individuals who can discuss both medical and NHP options for managing menopausal-related symptoms. Future studies are needed to evaluate the decision aid with women facing the decision regarding the use of NHP at menopause, including its effect on the patient/practitioner discussion.
